Sincere Bio's DLL3-Targeted CAR-T Therapy SNC115 Receives CDE IND Approval; China Leads Global DLL3 Pipeline Development

AbbVie Makes Bold Claim: Next Year, It Will Become the Largest CNS Company in the Industry!

On August 2, 2025, the clinical trial application for SNC115, a chimeric antigen receptor gene-modified T-cell injection targeting DLL3 submitted by Simnova, was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. The indication is for relapsed or refractory small cell lung cancer and/or other neuroendocrine cancers.

Source: CDE Official Website

SNC115 adopts an innovative design of armored structure with independent intellectual property rights, demonstrating superior efficacy compared to similar CAR designs in preclinical studies. Meanwhile, Simnova possesses mature and stable CMC capabilities for cell preparation, significantly reducing the ex vivo expansion time of T cells, shortening the waiting time for patients, which is particularly meaningful for advanced cancer patients.

DLL3 Target Blooming, China Takes the Lead

In the field of cancer treatment, it has been quiet for nearly20Year'sDLL3Target is reshaping small cell lung cancer (SCLC) with disruptive potential.SCLC) and the treatment landscape of other neuroendocrine tumors.2024Year, the world's firstDLL3Targeted TherapyTarlatamabObtainFDAAccelerated Approval for Market Launch, marking a major breakthrough in the transition of this target from theoretical exploration to clinical application, and breaking the deadlock for extensive-stage small cell lung cancer (ES-SCLC) Have long relied solely onPD-1The Dilemma of Combination Chemotherapy Brings New Hope to Patients.

"A single flower does not make a spring, but a hundred flowers in full bloom bring spring to the garden." According to the PatSnap database statistics,Globally Under ResearchDLL3Pipeline78Payment. Among them, in the clinical2Products in the period phase include4Individuals, in clinical1Products available in the period phase include13Unit.

DLL3The track brings together top pharmaceutical companies from around the world, and the competitive landscape is becoming increasingly intense. Chinese innovative pharmaceutical companies such as Hengrui and Innovent are expanding through external cooperation (BD) Rapidly expand and seize the opportunity; Novartis, Merck, etc.MNCThen, through acquisitions, accelerate the integration of cutting-edge technologies and buildCross-border and cross-technology platform stereoChemical Competition Network.

In terms of quantity,GlobalDLL3Among the research institutions, the number of Chinese pharmaceutical companies accounts for more than half, and their R&D status is also leading globally.Highlights the Rise of China's Innovative Power.

Data Source:PatSnap Database

Conclusion:Looking ahead, as clinical data from frontline treatments are gradually unveiled, along with bispecific antibodies,ADC, and the collaborative advancement of multiple technical pathways such as cell therapy,DLL3Target is expected to be“Potential Stock”Transforming into a new pillar of precision oncology treatment, offering patients more effective and less toxic treatment options, and ushering in a new chapter in the treatment of neuroendocrine tumors.

Image Source: Jimo AI

World's First Clinical Improvement! Sun Yat-sen Third Hospital Collaborates with Simnova to Advance Universal iPSC-Derived Neural Cell Therapy for Spinal Cord Injury

2025-08-04

Everest Medicines Increases Stake in I-Mab, Becomes Largest Shareholder

2025-08-02

AbbVie Makes Bold Claim: Next Year, It Will Become the Largest CNS Company in the Industry!

2025-08-02

Copyright Statement/Disclaimer

This article is an original piece.

This article is for information exchange purposes only and does not provide any commercial, medical, or investment advice.

The images, videos, fonts, music, and other materials in the article are either authorized genuine works purchased by PharmaTimes, sourced from the WeChat public image library, or taken from the company's official website/network. Some materials are used under the CC0 protocol, and the copyright belongs to the respective owners. PharmaTimes makes every effort to credit the sources.

If you have any questions, please contact us.

Sincerely grateful!

DrugTimes Official Website: www.drugtimes.cn

Contact Information:

Phone: 13651980212

WeChat: 27674131

Email: contact@drugtimes.cn

Click here to view more highlights!